TriangleDurvalumab (NCT03011814)
Durvalumab trial for Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma (NCT03011814). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for cutaneous or peripheral T cell lymphoma that has returned or not responded after at least two earlier systemic treatments.
The idea: restore the immune response against the lymphoma. Durvalumab is an antibody that blocks the PD-1 and PD-L1 checkpoint. Lenalidomide, an oral immune-modulating drug, may strengthen that effect.
In the phase 1 part, in cutaneous lymphoma, no dose-limiting toxicities were seen, and of 12 patients evaluable for response, 7 had partial responses. The phase 2 part randomizes patients to durvalumab alone or with lenalidomide. At City of Hope in Duarte, Christiane Querfeld leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.